Vaidya Sane Ayurved Laboratories Limited (NSE:MADHAVBAUG)

India · Delayed Price · Currency is INR

177.50

+5.00 (2.90%)

Oct 1, 2026, 3:12 PM IST

Market Cap	1.87B -38.8%
Revenue (ttm)	1.07B +16.6%
Net Income	89.87M +25.9%
EPS	8.04 +39.1%
Shares Out	10.52M
PE Ratio	22.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,600
Open	172.00
Previous Close	172.50
Day's Range	170.00 - 179.10
52-Week Range	147.00 - 335.00
Beta	0.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About NSE:MADHAVBAUG

Vaidya Sane Ayurved Laboratories Limited, together with its subsidiaries, engages in the research, development, and sale of ayurvedic medicines and products in India. The company sells medicines for arthritis and joint pains, cholesterol, diabetes, digestive, acidity, gastric, dyslipidemia, fever, cough, cold, general tonic, heart disease, hypertension/high blood pressure, liver, low glycemic index atta, obesity/weight management, piles and renal, skin, and wounds; and diet boxes, glow gorgeous cosmetics, health supplements, healthy breakfast, ... [Read more]

Industry Medical Care Facilities

Sector Healthcare

Founded 1999

Employees 413

Stock Exchange National Stock Exchange of India

Ticker Symbol MADHAVBAUG

Full Company Profile

Financial Performance

In fiscal year 2026, NSE:MADHAVBAUG's revenue was 1.07 billion, an increase of 16.58% compared to the previous year's 917.04 million. Earnings were 89.87 million, an increase of 25.93%.

Financial Statements